Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%

finance.yahoo.com/news/keros-therapeutics-stops-pah-drug-165409036.html

In This Article:
Keros Therapeutics Inc (NASDAQ:KROS) released topline data from the TROPOS Phase 2 trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (PAH) on Wednesday.
In December 2024, the company voluntarily halted…

This story appeared on finance.yahoo.com, 2025-05-29 16:54:09.
The Entire Business World on a Single Page. Free to Use →